Helen Collins, M.D., serves as the Chief Medical Officer at ENLIVEN THERAPEUTICS INC, a position that underscores her extensive experience and expertise in the field of medical oncology and drug development. Dr. Collins earned her medical degree from Johns Hopkins University School of Medicine, where she also completed her residency in internal medicine. Her passion for oncology led her to pursue a fellowship in medical oncology at the prestigious Memorial Sloan Kettering Cancer Center. Over the years, Dr. Collins has held several key positions in both academia and the pharmaceutical industry, contributing significantly to the development of novel cancer therapies. Throughout her career, Dr. Collins has been recognized for her groundbreaking work in targeted cancer therapies. She has authored numerous peer-reviewed articles and has been an invited speaker at major oncology conferences around the world. Her research has focused on understanding the molecular mechanisms of cancer and leveraging this knowledge to develop more effective treatments. Before joining ENLIVEN THERAPEUTICS INC, she served as the Vice President of Clinical Development at a leading biotech firm, where she oversaw the successful launch of several innovative oncology drugs. As Chief Medical Officer at ENLIVEN THERAPEUTICS INC, Dr. Collins plays a pivotal role in guiding the company's clinical development strategy. She leads a team of dedicated professionals in designing and executing clinical trials that aim to bring new hope to patients with cancer. Her strategic vision and commitment to advancing cancer care are instrumental in driving the company's mission to develop transformative therapies. Under her leadership, ENLIVEN THERAPEUTICS INC continues to make significant strides in the fight against cancer, positioning itself as a leader in the oncology space.